Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetylcarnitine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.65 |
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 0.45 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 0.45 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.45 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.45 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.45 |
| ▸ | GRIN2C known ✓ | Q14957 | 1/20 | 0.45 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 1/20 | 0.45 |
| ▸ | HSP90AA1 known ✓ | P07900 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.65 |
| ▸ | MEN1 | O00255 | 4/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | SLC25A20 | O43772 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetylcarnitine SCHEMBL6635550 | 1.00 | CYP1A2 (0.65) | CYP1A2MEN1KMT2AHRH1LMNA | |
| Acetylcarnitine SCHEMBL7536321 | 0.99 | CYP1A2 (0.67) | CYP1A2MEN1KMT2AHRH1LMNA | |
| Acetylcarnitine SCHEMBL7536313 | 0.99 | CYP1A2 (0.67) | CYP1A2MEN1KMT2AHRH1LMNA | |
| Acetylcarnitine SCHEMBL6634467 | 0.91 | KMT2A (0.63) | CYP1A2MEN1KMT2AHRH1LMNA | |
| Acetylcarnitine SCHEMBL6634470 | 0.91 | KMT2A (0.63) | CYP1A2MEN1KMT2AHRH1LMNA | |
| Acetylcarnitine SCHEMBL6634229 | 0.88 | MEN1 (0.70) | CYP1A2MEN1KMT2AHRH1LMNA | |
| Acetylcarnitine SCHEMBL6634231 | 0.88 | MEN1 (0.70) | CYP1A2MEN1KMT2AHRH1LMNA | |
| Acetylcarnitine SCHEMBL5429939 | 0.88 | MEN1 (0.65) | CYP1A2MEN1KMT2AHRH1LMNA | |
| Acetylcarnitine SCHEMBL5429930 | 0.88 | MEN1 (0.65) | CYP1A2MEN1KMT2AHRH1LMNA | |
| Acetylcarnitine SCHEMBL7542732 | 0.87 | MEN1 (0.72) | CYP1A2MEN1KMT2AHRH1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1202956-B1 | THERAPEUTICALLY AND/OR NUTRITIONALLY ENHANCED DERIVATIVES OF ACTIVE INGREDIENTS AND ORALLY ADMINISTRABLE COMPOSITIONS CONTAINING SAME | SIGMA TAU IND FARMACEUTI (IT) | 2004-05-19 | — | — | EP | claimed |
| EP-1202956-A1 | THERAPEUTICALLY AND/OR NUTRITIONALLY ENHANCED DERIVATIVES OF ACTIVE INGREDIENTS AND ORALLY ADMINISTRABLE COMPOSITIONS CONTAINING SAME | Biosalts S.r.l. (IT) | 2002-05-08 | — | — | EP | claimed |
| WO-2000073258-A1 | THERAPEUTICALLY AND/OR NUTRITIONALLY ENHANCED DERIVATIVES OF ACTIVE INGREDIENTS AND ORALLY ADMINISTRABLE COMPOSITIONS CONTAINING SAME | BIOSALTS S.R.L. (IT) | 2000-12-07 | — | — | WO | claimed |
| US-6703042-B1 | STABLE, NON-HYGROSCOPIC; NUTRITIONAL SUPPLEMENTS | SIGMA-TAU INDUSTRIES FARMACEUTICHE RIUNITE S.P.A. (IT) | 2004-03-09 | — | — | US | disclosed |